



ESSEN  
DÜSSELDORF  
COLOGNE


CLINIC MEETS BIOLOGY

# WEST GERMAN LYMPHOMA SYMPOSIUM

PROGRAM

May 21–23, 2026

Conference Center Essen | Germany



## CONTACT

### Scientific lead and responsible for the program



**Universitätsmedizin Essen**

Department of Haematology and Stem Cell Transplantation  
West German Cancer Center  
University Hospital Essen (AÖR)  
Hufelandstraße 55, 45147 Essen (GER)

### Under the patronage of

Unter der Schirmherrschaft der



**Josep Carreras**  
LEUKAEMIA  
Research Institute

### In cooperation with



### Meeting Office / Organizer and Contact

CSi Hamburg GmbH  
Goernestraße 30, 20249 Hamburg (GER)  
+49 40 30770 300  
meetings@csihamburg.de



### Venue

Conference Center Essen  
Huysenallee 53  
45128 Essen (GER)  
Nordrhein-Westfalen (NRW)

### Hybrid Event

To follow the live stream with Q&A  
[www.lymphoma-symposium.de/stream](http://www.lymphoma-symposium.de/stream)  
password: Lym-Sym26  
(instructions will be shown)



### WLAN

SSID: ClinicmeetsBiology  
PW: Lymphoma2026

### Media library

Contributions - video on demand  
available from  
Tuesday, May 26, 2026  
12:00 (CET)



SCAN ME

## WELCOME

### Dear Colleagues and Friends

Welcome to the West German Lymphoma Symposium here in Essen.

Following the inaugural meeting in 2024, we are pleased to continue this format and to welcome you as part of a growing scientific community. The strong exchange during the first symposium confirmed the need for a dedicated forum that brings together regional and international expertise in preclinical and clinical lymphoma research.

The field is evolving rapidly. Advances in molecular understanding, improved mouse models and progress in preclinical drug development are reshaping research and treatment. New therapeutic strategies, including CART-cells, bispecific antibodies and next-generation small molecules, are increasingly entering clinical practice.

At the same time, the Comprehensive Cancer Centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have further strengthened their collaboration. The establishment of the National Center for Tumor Disease West (NCT-West) in Essen and Cologne supports strong clinical and translational lymphoma programs and aims to inspire the next generation of researchers.

We are very pleased to have you with us and hope you enjoy the scientific program and the discussions.

Abstracts submitted to this meeting are presented in short talks and the poster session, with selected contributions receiving awards.

With all our best wishes and warm regards  
Conference chairs and program committee members

#### **Christian Reinhardt**

**Bastian von Tresckow, Ralf Küppers, Stefan Alig**

University Hospital Essen, West German Cancer Center

#### **Peter Borchmann**

University Hospital Cologne, Clinic for Internal Medicine  
Oncology/Hematology

#### **Sascha Dietrich**

University Hospital Düsseldorf, Clinic for Hematology,  
Oncology and Clinical Immunology

#### **Ari M. Melnick**

Josep Carreras Leukaemia,  
Research Institute Barcelona

Day 1 | Thursday, May 21, 2026

from 12:30	Registration and Networking
<b>1:45</b>	<b>Opening and welcome</b> Scientific committee
<b>2:00–4:05</b>	<b>SESSION 1</b> <b>Epigenetic rewiring in aggressive lymphoma</b> Chair Christian Reinhardt, University Hospital Essen (GER)
.....	
<b>2:00</b>	<b>DNA-methylation based classification of lymphomas: A tool to come?</b> Reiner Siebert, Ulm University Hospital (GER)
<b>2:25</b>	<b>TBA</b> Björn Chapuy, Charité University Medicine Berlin (GER)
<b>2:50</b>	<b>Epigenetic regulation of lymphoma cell states</b> Michael R. Green, MD Anderson Cancer Center, Houston (USA)
<b>3:15</b>	<b>How the immune system becomes malignant reveals novel therapeutic vulnerabilities</b> Ari M. Melnick, Josep Carreras Leukaemia (ES)
<b>3:40</b>	<b>Decoding malignant B cell plasticity in aggressive lymphomas</b> Sandrine Roulland, CIML-Centre d' Immunologie, Marseille-Luminy (FR)
4:05–4:30	Break

4:30–7:00

**SESSION 2**

**Harnessing the immune system for lymphoma therapy - I**

**Chairs**

Georg Lenz, University Hospital Münster (GER)

Bastian von Tresckow, University Hospital Essen (GER)

.....

4:30

**Targeting Oncogenic Chromatin Remodeling in Lymphoma**

Darko Barisic, Weill Cornell Medicine New York (USA)

4:55

**Reprogramming the lymphoma immune microenvironment for therapy**

Wendy Béguelin, Langone Health NYU, New York (USA)

5:20

**Cytokine-associated Immune Remodeling in Follicular Lymphoma Transformation**

Erin M. Parry, Harvard Medical School, Dana-Farber Cancer Institute, Boston (USA)

5:45

**Therapeutic targeting the lymphoma micro environment to improve CAR T-cell response in aggressive B-cell lymphoma**

Roland Ullrich, University Hospital Cologne (GER)

6:10

**The biology of high-risk B-cell malignancies**

Thomas Oellerich, University Medical Center Frankfurt (GER)

6:35

**Mechanisms of immune evasion in molecular subtypes of diffuse large B-cell lymphoma BA**

Margaret Shipp, Dana Farber/Harvard Cancer Center, Boston (USA)

7:00–9:00

**Get-together**

Day 2 | Friday, May 22, 2026

9:00–11:05

**SESSION 3**

**Harnessing the immune system for lymphoma therapy - II**

Chairs

Peter Borchmann, University Hospital Cologne (GER)

Ralf Küppers, University Hospital Essen (GER)

.....

9:00

**Recent developments in T-cell engaging antibodies for the treatment of B-cell lymphomas**

Martin Hutchings, University of Copenhagen (DK)

9:25

**B cell lymphoma development in the thymic niche**

Christian Steidl, Centre for Lymphoid Cancer, Vancouver (CAN)

9:50

**Primary analysis of the GHSB Pembro-CORE trial**

Bastian von Tresckow, University Hospital Essen (GER)

10:15

**Harnessing functional genomic screens to elucidate DLBCL biology**

Sebastian Scheich, University Hospital Frankfurt (GER)

10:40

**Novel mouse models of DLBCL**

Christian Reinhardt, University Hospital Essen (GER)

11:05–11:30

Break

11:30–1:35

**SESSION 4**

**Towards chemo-free treatment of lymphoma**

Chairs

Stefan Alig, University Hospital Essen (GER)

Sascha Dietrich, University Hospital Düsseldorf (GER)

.....

11:30

**Progress Made, Obstacles Remaining: anti-PD1 First-Line Treatment of cHL**

Paul Bröckelmann, University Hospital of Cologne (GER)

11:55

**Towards improved outcomes for p53 mutant blood cancers**

Gemma Kelly, Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne (AUS)

12:20

**Proteogenomics and Precision Medicine**

James Phelan, National Cancer Institute, Bethesda (USA)

Day 2 | Friday, May 22, 2026


- 12:45**                    **Targeted Therapy Approaches in Aggressive B-cell Lymphoma**  
Mark Roschewski, National Cancer Institute, Bethesda (USA)
- 1:10**                      **Frontline DLBCL Therapy in 2036: Chaos of Choice?**  
Jason Westin, University of Texas MD Anderson Cancer, Center Houston (USA)
- 1:35–2:45                Break
- 2:45–4:25**                **SESSION 5**  
**At the interface between biological and chemical engineering**  
**Chairs**  
Ralf Küppers, University Hospital Essen (GER)  
Christian Reinhardt, University Hospital Essen (GER)
- 2:45**                      **New targets and technologies for CAR T cells in lymphoma**  
Michael Hudecek, University Hospital Würzburg (GER)
- 3:10**                      **Same but different: on the role of B cells in cellular therapies**  
Sebastian Kobold, LMU Klinikum, Munich (GER)
- 3:35**                      **Development of PROTACs as New Pharmacological Modalities  
for the Treatment of Cancer**  
Stefan Knapp, Goethe-University Frankfurt (GER)
- 4:00**                      **Linking Elongation Factors and Lysine Acetyltransferases to  
Cancer Cell Death using Chemically Induced Proximity**  
Roman Sarott, Max-Planck-Institute for Medical Research, Heidelberg (GER)
- 4:30–6:30**                **POSTER PRESENTATION**

**NEU** beim  
**2L+ DLBCL NOS**  
ASCT-ungeeignet\*

Roche

# MIT DIESER OS-KURVE IST ALLES GESAGT\*\*

COLUMVI® i.v. + GemOx **verdoppelt**  
das **mediane OS** auf **25,5 Monate**.<sup>1,#</sup>



Für mehr Informationen  
einfach QR-Code scannen.

 **COLUMVI**  
glofitamab

EMPOWERING  
HEMATOLOGY

 **POLIVY**

 **COLUMVI** ▼

 **Lunsumio** ▼

 **GAZYVARO**

 **PiaSky** ▼

Arzneimittel, die mit einem ▼ gekennzeichnet sind, unterliegen einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Bitte melden Sie Nebenwirkungen an die Roche Pharma AG unter [grenzach.drug\\_safety@roche.com](mailto:grenzach.drug_safety@roche.com) oder Fax +49 7624 14 3183 oder die zuständige Bundesoberbehörde unter [www.pei.de](http://www.pei.de) oder [www.bfarm.de](http://www.bfarm.de) (PEI/BfArM) oder Fax: +49 6103/77-1234 (PEI) bzw. Fax: +49 228/207-5207 (BfArM).

\* Columvi in Kombination mit Gemcitabin und Oxaliplatin wird angewendet zur Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem diffus großzelligem B-Zell-Lymphom, das nicht anderweitig spezifiziert ist (DLBCL NOS), und Patienten, die nicht für eine autologe Stammzelltransplantation (ASCT) geeignet sind.

\*\* In der STARGLO-Studie betrug das mediane, vom Prüfarzt beurteilte Gesamtüberleben (OS) 25,5 Monate (95%-KI: 18,3-NE) mit Columvi + GemOx, verglichen mit 12,9 Monaten (95%-KI: 7,9-18,5) mit R-GemOx (HR 0,62 [95%-KI: 0,43-0,88]); Datenschnitt Februar 2024.

# Im Vergleich zu R-GemOx.

**2L:** zweite Therapielinie; **ASCT:** Autologe Stammzelltransplantation; **DLBCL:** diffuses großzelliges B-Zell-Lymphom; **GemOx:** Gemcitabin und Oxaliplatin; **i.v.:** intravenös; **NE:** nicht auswertbar; **NOS:** nicht anderweitig spezifiziert; **OS:** Gesamtüberleben; **R-GemOx:** Rituximab, Gemcitabin und Oxaliplatin.

**1.** Abramson JS, et al. Lancet. 2024; 404: 1940-54.



Zu den Pflichtangaben  
[go.roche.de/haema\\_PA](http://go.roche.de/haema_PA)



**4:30–6:30 POSTER PRESENTATION**

The poster presentation is divided into 4 poster walks. Per poster: introduction/presentation 5 minutes + 5 minutes discussion. The two best poster presentations will be honored with a poster prize, during the closing ceremony.

**PO\_A1 to PO\_A11**

Chair: Sascha Dietrich, University Hospital Duesseldorf (GER)

**PO\_A1** **DDX3X and DDX3Y dosage imbalance drives sex bias in Burkitt lymphoma.**  
**K. Helian**<sup>1</sup>, C. Gong<sup>1</sup>, J. Coleman<sup>2</sup>, V. Aggarwal<sup>1</sup>, J. Krupka<sup>1</sup>, S. Brocklesby<sup>1</sup>,  
R. Gilbertson<sup>2</sup>, D. Hodson<sup>1</sup>

<sup>1</sup> University of Cambridge, Cambridge Stem Cell Institute & Department of Haematology, Cambridge, United Kingdom

<sup>2</sup> University of Cambridge, CRUK Cambridge Institute & Department of Oncology, Cambridge, United Kingdom

**PO\_A2** **Cell clones containing BCOR frameshift mutations in the first coding exons of the gene retain BCOR protein expression**

**Y. Yozbatiran**<sup>1</sup>, W. Sura<sup>1</sup>, S. Sunder<sup>1</sup>, Z. Drozdowska<sup>1</sup>, K. Bednarek<sup>1</sup>,  
M. Kostrzewska-Poczekaj<sup>1</sup>, M. Giefing<sup>1</sup>

<sup>1</sup> Institute of Human Genetics, Polish Academy of Sciences, Cancer Genetics, Poznań, Poland

**PO\_A3** **NFDI4Immuno: A shared database for immunology research data**

**A. Kadam**<sup>1</sup>, B. Budeus<sup>1</sup>

<sup>1</sup> Uniklinikum Essen, Institute of Cell Biology, Essen, Germany

**PO\_A4** **Functional role of AKT isoforms in Hodgkin Lymphoma**

**M. Marra**<sup>1</sup>, R. Küppers<sup>2</sup>, M. Jücker<sup>1</sup>

<sup>1</sup> University Medical Center Hamburg Eppendorf, Institute of Biochemistry and Signal Transduction, Hamburg, Germany

<sup>2</sup> University Duisburg-Essen, Institute of Cell Biology, Essen, North Rhine-Westphalia, Germany

**PO\_A5** **Establishing a scalable manufacturing process for genetically modified  $\gamma\delta$  T cells for preclinical research**

**S. Nickel**<sup>1</sup>, K. Hoerster<sup>1</sup>, M. Soldierer<sup>2</sup>, H. Hanenberg<sup>2,3</sup>, C. Reinhardt<sup>1</sup>,  
B. von Tresckow<sup>1</sup>

<sup>1</sup> University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

<sup>2</sup> University Hospital Essen, Department of Pediatrics III, University Children's Hospital Essen, University Duisburg-Essen, Essen, Germany

<sup>3</sup> University Hospital Düsseldorf, Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany

**PO\_A6**

**Shift towards a more naive phenotype of the T-cell compartment in patients with aggressive B-cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy**

**V. C. Ridder**<sup>1</sup>, K. Hoerster<sup>1</sup>, S. Nickel<sup>1</sup>, P. B. Ridder<sup>2</sup>, M. Teichert<sup>1</sup>, J. Puthenparambil<sup>1</sup>, H. C. Reinhardt<sup>1</sup>, B. von Tresckow<sup>1</sup>

<sup>1</sup> Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, North Rhine-Westphalia, Germany

<sup>2</sup> Knappschaft Kliniken University Hospital Bochum, Center for Artificial Intelligence, Medical Informatics and Data Science, Bochum, North Rhine-Westphalia, Germany

**PO\_A7**

**Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma**

M. Nowicka<sup>5</sup>, W. Leung<sup>1</sup>, C. Carlo-Stella<sup>2</sup>, M. Dickinson<sup>3</sup>, M. Hutchings<sup>4</sup>, E. Mulvihill<sup>5</sup>, L. Lundberg<sup>5</sup>, H. Hamidi<sup>1</sup>, **A. Bottos**<sup>5</sup>

<sup>1</sup> Genentech, San Francisco, United States of America

<sup>2</sup> Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

<sup>3</sup> Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

<sup>4</sup> Rigshospitalet, Copenhagen, Denmark

<sup>5</sup> F. Hoffmann-La Roche, Basel, Switzerland

**PO\_A8**

**Mechanisms of humoral immune dysfunction in the Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia**

**A. Beyer**<sup>1</sup>, G. Knittel<sup>1</sup>, S. Höfmann<sup>1</sup>, A. W. Tabatabai<sup>1</sup>, M. Möllmann<sup>1</sup>, P.-H. Nguyen<sup>3</sup>, R. Zölzer<sup>3</sup>, S. P. Koziel<sup>4</sup>, P.-M. Bruch<sup>4</sup>, R. Küppers<sup>2</sup>, H. C. Reinhardt<sup>1</sup>

<sup>1</sup> University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

<sup>2</sup> University Hospital Essen, Institute for Cell Biology (Tumor Research), Essen, North Rhine-Westphalia, Germany

<sup>3</sup> Center for Molecular Medicine Cologne, Department I of Internal Medicine, Cologne, North Rhine-Westphalia, Germany

<sup>4</sup> University Hospital Düsseldorf, Department of Haematology, Oncology and Clinical Immunology, Düsseldorf, North Rhine-Westphalia, Germany

**PO\_A9**

**NR4A1 Loss Drives Immune Checkpoint Upregulation and CD8<sup>+</sup> T Cell Dysfunction in Aggressive Lymphoma**

**K. Pansy<sup>1</sup>, S. Haingartner<sup>1</sup>, A. Deutsch<sup>1</sup>**

<sup>1</sup>Medical University of Graz, Division of Hematology, Graz, Steiermark, Austria

**PO\_A10**

**Deciphering the Pathomechanisms of HIV-Associated Lymphomas**

**V. Berg<sup>1</sup>, N. Kahlert<sup>1</sup>, K. Danielzik<sup>3</sup>, A. Rosenwald<sup>4</sup>, G. Ott<sup>5</sup>, A. Ross<sup>12</sup>, M. Dampmann<sup>2</sup>, S. Dolff<sup>6</sup>, S. Hartmann<sup>9</sup>, P. Möller<sup>8</sup>, M. Hummel<sup>10</sup>, S. Esser<sup>7</sup>, L. Thurner<sup>11</sup>, D. Hoffmann<sup>3</sup>, B. Budeus<sup>1</sup>, R. Küppers<sup>1</sup>**

<sup>1</sup>University Hospital Essen, Institute of Cell Biology (Tumor Research), Essen, Germany

<sup>2</sup>University Hospital Essen, West German Tumor Center, Essen, Germany

<sup>3</sup>University of Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, Germany

<sup>4</sup>University of Würzburg, Institute of Pathology, Würzburg, Germany

<sup>5</sup>Robert Bosch Hospital, Institute of Pathology, Stuttgart, Germany

<sup>6</sup>University Hospital Essen, Department of Infectiology, Essen, Germany

<sup>7</sup>University Hospital Essen, Department of Dermatology, Essen, Germany

<sup>8</sup>University Hospital Ulm, Department of Pathology, Essen, Germany

<sup>9</sup>University Hospital Essen, Department of Pathology, Essen, Germany

<sup>10</sup>Charité University Medicine, Institute of Pathology, Berlin, Germany

<sup>11</sup>University Hospital Saarland, José Carreras Center, Homburg, Germany

<sup>12</sup>University of Duisburg-Essen, Therapy Research in Neurogeriatrics, Essen, Germany

**PO\_A11**

**Immunosurveillance of premalignant germinal center B cells**

**L. Zhang<sup>1,2</sup>, M. S. Hung<sup>1</sup>, O. Atkins<sup>1</sup>, P. Artemov<sup>3</sup>, A. Sochon<sup>1</sup>, V. Boulat<sup>1</sup>, H. C. Reinhardt<sup>4</sup>, J. Okosun<sup>3</sup>, D. P. Calado<sup>1,2</sup>**

<sup>1</sup>The Francis Crick Institute, London, United Kingdom

<sup>2</sup>Babraham Institute, Cambridge, United Kingdom

<sup>3</sup>Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

<sup>4</sup>University Hospital Essen, Essen, Germany

**PO\_B1 to PO\_B11**

Chair: Bastian von Tresckow, University Hospital Essen (GER)

**PO\_B1 High-throughput, functional profiling of every DLBCL hotspot mutation in human germinal centre B cells**

**J. Mateos-Jaimez**<sup>1</sup>, G. Shevchenko<sup>1</sup>, V. Jiménez-Martínez<sup>2,3</sup>, I. Moutsopoulos<sup>1</sup>, E. Whittle<sup>1</sup>, C. Gong<sup>1</sup>, A. Yang<sup>1</sup>, R. E. Fenner<sup>1</sup>, M. Di Re<sup>1</sup>, Y. Wang<sup>1</sup>, M. Barile<sup>1</sup>, X. Ju<sup>1</sup>, L. M. Staudt<sup>7</sup>, R. F. Pérez<sup>2,6</sup>, J. I. Martin-Subero<sup>2,5</sup>, D. J. Hodson<sup>1</sup>

<sup>1</sup> University of Cambridge, Department of Haematology, Cambridge, United Kingdom

<sup>2</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

<sup>3</sup> University of Barcelona, Barcelona, Spain

<sup>4</sup> Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

<sup>5</sup> Complutense University of Madrid, Department of Biochemistry and Molecular Biology, Madrid, Spain

<sup>6</sup> National Cancer Institute, Bethesda, United States of America

**PO\_B2 IGH enhancer RNAs - new players in B-cell lymphoma**

**A. Kompaniets**<sup>1</sup>, J. Przybył<sup>1</sup>, K. Rassek<sup>1</sup>, M. Kasprzyk<sup>1</sup>, W. Sura<sup>1</sup>, N. Rozwadowska<sup>1</sup>, A. Dzikiewicz-Krawczyk<sup>1</sup>

<sup>1</sup> Institute of Human Genetics Polish Academy of Sciences, Molecular Pathology, Poznań, Poland

**PO\_B3 Mechanisms of humoral immune dysfunction in CLL**

**M. M. Elbert**<sup>1</sup>, M. Dampmann<sup>2,3</sup>, N. Kahlert<sup>1</sup>, J. von Tresckow<sup>2,4</sup>, A. Kibler<sup>5</sup>, H. C. Reinhardt<sup>2,6</sup>, G. Knittel<sup>2</sup>, B. Budeus<sup>1</sup>, R. Küppers<sup>1,6</sup>

<sup>1</sup> University Medicine Essen, Institute of Cell Biology (Cancer Research), Essen, North Rhine-Westphalia, Germany

<sup>2</sup> University Medicine Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

<sup>3</sup> West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, North Rhine-Westphalia, Germany

<sup>4</sup> St. Josef-Hospital, Ruhr-University Bochum clinics, Bochum, North Rhine-Westphalia, Germany

<sup>5</sup> University Medicine Essen, Department of Immunodynamics, Institute for Experimental Immunology and Imaging, Essen, North Rhine-Westphalia, Germany

<sup>6</sup> German Cancer Research Center, German Cancer Consortium (DKTK), Essen, Baden-Württemberg, Germany

- PO\_B4**                      **Mechanisms of immune evasion in aggressive B cell lymphomas**  
**C. Brombach**<sup>1,2</sup>, E. Sidiropoulou<sup>1,3</sup>, S. Kim<sup>4,5</sup>, N. Serin<sup>6</sup>, N. Aubert<sup>2</sup>,  
J. Ihlow<sup>4</sup>, B. Chapuy<sup>6</sup>, M. Seiffert<sup>2</sup>, S. Sander<sup>5,1</sup>  
<sup>1</sup>German Cancer Research Center (DKFZ), Adaptive Immunity and Lymphoma, Heidelberg, Germany  
<sup>2</sup>German Cancer Research Center (DKFZ), Molecular Genetics, Heidelberg, Germany  
<sup>3</sup>German Cancer Research Center (DKFZ), Immune Diversity, Heidelberg, Germany  
<sup>4</sup>Charité Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany  
<sup>5</sup>University Medicine Greifswald, Greifswald, Comprehensive Cancer Center Mecklenburg Vorpommern, Greifswald, Germany  
<sup>6</sup>Charité Universitätsmedizin Berlin, 6 Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Berlin, Germany
- PO\_B5**                      **Hyperthermia increases ferroptosis susceptibility of diffuse large B-cell lymphoma**  
**M. Franke**<sup>1</sup>, A. Schmitt<sup>1</sup>, G. Lenz<sup>1</sup>, S. Hailfinger<sup>1</sup>  
<sup>1</sup>University Hospital Münster, Department of Medicine A, Hematology, Oncology and Pneumology, Münster, North Rhine-Westphalia, Germany
- PO\_B6**                      **T-Cell Exhaustion and Myeloid Rewiring During Murine CLL Progression Uncovered by High-Dimensional Spectral Cytometry**  
**H. Briesch**<sup>1,3</sup>, M. Coelho<sup>1,3</sup>, N. Aubert<sup>1</sup>, A. Floerchinger<sup>1,3</sup>, D. Medina Gil<sup>1</sup>, M. Günter<sup>4</sup>, M. Zapatka<sup>2</sup>, S. E. Autenrieth<sup>4</sup>, M. Seiffert<sup>1</sup>  
<sup>1</sup>German Cancer Research Center (DKFZ), Immune Modulation in Cancer, Heidelberg, Germany  
<sup>2</sup>German Cancer Research Center (DKFZ), Molecular Genetics, Heidelberg, Germany  
<sup>3</sup>Heidelberg University, Faculty of Biosciences, Heidelberg, Germany  
<sup>4</sup>German Cancer Research Center (DKFZ), Dendritic cells in Infection and Cancer, Heidelberg, Germany
- PO\_B7**                      **An extended ex vivo HSC expansion platform enables rapid, multiplex in vivo functional genomics for lymphoma**  
**H. Bilboe**<sup>1</sup>, C. Gong<sup>1</sup>, A. Wilkinson<sup>1</sup>, D. Hodson<sup>1</sup>  
<sup>1</sup>University of Cambridge, Department of Haematology, Cambridge, United Kingdom
- PO\_B8**                      **Identification and characterization of somatic mutations in ZC3H12A in ABC DLBCL**  
**F. Eberstadt**<sup>1</sup>, M. Wang<sup>2</sup>, B. Chapuy<sup>2</sup>, D. Krappmann<sup>1</sup>  
<sup>1</sup>Helmholtz Munich, SAT - AG Krappmann, Munich, Bavaria, Germany  
<sup>2</sup>Charité Universitätsmedizin Berlin, Translationale Lymphomforschung, Leitung Lymphome, Berlin, Germany

**PO\_B9**

**In search of lost ORFs: high confidence map of noncanonical Open Reading Frames in lymphoid cells**

**J. A. Krupka**<sup>1,2</sup>, E. Whittle<sup>1,2</sup>, K.H. J. Tan<sup>1,2</sup>, G. Shevchenko<sup>1,2</sup>, R. Jackson<sup>1,2</sup>, C. Gong<sup>1,2</sup>, J. Gao<sup>1,2</sup>, D. J. Hodson<sup>1,2</sup>

<sup>1</sup> University of Cambridge, Department of Haematology, Cambridge, United Kingdom

<sup>2</sup> University of Cambridge, Cambridge Stem Cell Institute, Cambridge, United Kingdom

**PO\_B10**

**Circulating Tumor DNA Reveals Lymphoma-Associated Mutations Long Before Clinical Diagnosis**

**N. Veltmaat**<sup>1,3</sup>, Y. Zhong<sup>1,3</sup>, I. van Zeventer<sup>1</sup>, J. Kluiver<sup>2,3</sup>, A. Diepstra<sup>2,3</sup>, A. van den Berg<sup>2,3</sup>, W. Plattel<sup>1,3</sup>, M. Nijland<sup>1,3</sup>

<sup>1</sup> University Medical Center Groningen, Hematology, Groningen, Netherlands

<sup>2</sup> University Medical Center Groningen, Pathology and Medical Biology, Groningen, Netherlands

<sup>3</sup> University Medical Center Groningen, Lymphoma Research Groningen, Groningen, Netherlands

**PO\_B11**

**In vivo production of bispecific antibodies against hematological malignancies**

**Y. Yang**<sup>1</sup>, M. Freihammer<sup>1</sup>, R. Flümman<sup>1</sup>, A. Lütz<sup>1</sup>, J. Petri<sup>1</sup>, M. Michalik<sup>1</sup>, S. Borchmann<sup>1,2</sup>

<sup>1</sup> University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany

<sup>2</sup> German Hodgkin Study Group, Cologne, Germany

**PO\_C1 to PO\_C11**

Chair: Stefan Alig, University Hospital Essen (GER)

- PO\_C1** **Defining Functional Subgroups and Novel Oncogenic Addictions in Burkitt Lymphoma via Genome-wide CRISPR/Cas9 Screening**  
**A. K.P. Götz**<sup>1</sup>, S. P. Chillappagari<sup>1</sup>, S. Becker<sup>1</sup>, R. Kumar<sup>2</sup>, M. Braun<sup>3</sup>, A. Bräuninger<sup>1</sup>, D. Körholz<sup>3</sup>, S. Gattenlöhner<sup>1</sup>, R. Schmitz<sup>1</sup>  
<sup>1</sup>Justus-Liebig University, Institute for Pathology, Gießen, Germany  
<sup>2</sup>Indian Institute of Technology, Department of Biotechnology, Hyderabad, India  
<sup>3</sup>Justus-Liebig University, Pediatric Hematology and Oncology Department, Gießen, Germany
- PO\_C2** **Elucidation of transcriptomic tumor cell heterogeneity and microenvironment in classic Hodgkin lymphoma**  
**F. Schramm**<sup>1</sup>, S. Klotz<sup>1</sup>, B. Budeus<sup>1</sup>, L. Beeck<sup>1</sup>, M. Weniger<sup>1</sup>, P. Bröckelmann<sup>2</sup>, R. Küppers<sup>1</sup>  
<sup>1</sup>University medicine Essen, Institute for Cellbiology (Tumor Research), Essen, Germany  
<sup>2</sup>University Hospital of Cologne, Max Planck Institute for Biology of Ageing, Cologne, Germany
- PO\_C3** **Prognostic Value of the Glasgow Prognostic Score in a Slovene Cohort of Patients with Nodal T-Follicular Helper Cell Lymphoma**  
**G. Gašljević**<sup>1,2</sup>, R. Arko<sup>3</sup>, E. Erzar<sup>4</sup>, V. Sindi-Ivanova<sup>5</sup>, S. Dirnhofer<sup>5</sup>, A. Tzankov<sup>5</sup>, V. Kloboves-Prevodnik<sup>6,2</sup>, P. Dora<sup>1</sup>, M. Kokelj<sup>6</sup>, L. Boltežar<sup>3</sup>  
<sup>1</sup>Institute of Oncology Ljubljana, Department of Pathology, Ljubljana, Slovenia  
<sup>2</sup>University of Maribor, Faculty of Medicine, Maribor, Slovenia  
<sup>3</sup>Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia  
<sup>4</sup>Tissue Typing Centre, Slovenian Institute for Transfusion Medicine, Ljubljana, Slovenia  
<sup>5</sup>University Hospital Basel, University of Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland  
<sup>6</sup>Institute of Oncology Ljubljana, Department of Cytopathology, Ljubljana, Slovenia
- PO\_C4** **Rituximab-induced liquid biopsy signatures inform on cellular and microenvironmental contexts in B-Cell Lymphoma patients**  
S. Tehrani Fateh<sup>1,2</sup>, G. Greiner<sup>1,2</sup>, W.-K. Hofmann<sup>2</sup>,  
**K. Clemm von Hohenberg**<sup>1,2</sup>  
<sup>1</sup>German Cancer Research Center (DKFZ) Heidelberg, Junior Clinical Cooperation Unit Translational Lymphoma Research, Mannheim, Germany  
<sup>2</sup>University Medicine Mannheim, Department of Hematology/Oncology, Mannheim, Germany

- PO\_C5**                    **Niche eviction via CD49d targeting sensitises BM-tropic DLBCL to CD3×CD20 bispecifics**  
**N. Aubert**<sup>1</sup>, H. Briesch<sup>1</sup>, A. Floerchinger<sup>1</sup>, D. Calado<sup>2,3</sup>, M. Seiffert<sup>1</sup>  
<sup>1</sup>DKFZ, B060 Molecular Genetics, Heidelberg, Baden-Württemberg, Germany  
<sup>2</sup>Francis Crick Institute, Immunity & Cancer Laboratory, London, United Kingdom  
<sup>3</sup>Babraham Institute, Cambridge, United Kingdom
- PO\_C6**                    **B Cell Differentiation in the Germinal Centre Reaction**  
**A.-K. Schnormeier**<sup>1</sup>, B. Höing<sup>3</sup>, B. Budeus<sup>1</sup>, M. Weniger<sup>1</sup>, D. Hoffmann<sup>2</sup>, R. Küppers<sup>1</sup>  
<sup>1</sup>University of Duisburg-Essen, Institute of Cell Biology (Tumor Research), Essen, Germany  
<sup>2</sup>University of Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, Germany  
<sup>3</sup>University Medical Center, Otolaryngology, Essen, Germany
- PO\_C7**                    **The Clinico-Genomic Lymphoma Dataset Explorer (CLYDE): A Comparative Analysis of High-Throughput DNA Sequencing Datasets of Diffuse Large B-Cell Lymphoma**  
**J. Zhou**<sup>1,2</sup>, F. Ullrich<sup>1</sup>, M. Nezamabadi<sup>1,2</sup>, C. Reinhardt<sup>1</sup>, B. von Tresckow<sup>1</sup>, E. Kocakavuk<sup>1, 2</sup>  
<sup>1</sup>University Hospital Essen, Dept of Hematology and Stem Cell Transplantation, West German Cancer Center, NCT-West, Essen, Germany  
<sup>2</sup>University Hospital Essen, Institute for AI in Medicine (IKIM), Essen, Germany
- PO\_C8**                    **Zonation mapping of the neuro-immune-tumor crosstalk in primary central nervous system lymphoma via spatial transcriptomics**  
**Q. Shi**<sup>1,2</sup>, Y. Su<sup>1,2</sup>, Y. Zhou<sup>3</sup>, C. Reinhardt<sup>1</sup>, B. von Tresckow<sup>1</sup>, F. Rambow<sup>2</sup>, C. Mlynarczyk<sup>3</sup>, E. Kocakavuk<sup>1,2</sup>  
<sup>1</sup>Universitätsklinikum Essen, Hematology and Stem Cell Transplantation, West German Cancer Center, Essen, Germany  
<sup>2</sup>Universitätsklinikum Essen, Institute for Artificial Intelligence in Medicine, Essen, Germany  
<sup>3</sup>Yale University, Yale School of Medicine, CE, United States of America

- PO\_C9**                    **Single-nucleus RNA-sequencing of central nervous system lymphoma (CNSL)**  
**Y. Su**<sup>1,2</sup>, H. Dong<sup>2</sup>, F. Ullrich<sup>1</sup>, K. Keyvani<sup>3</sup>, S. Hartmann<sup>4</sup>, C. Reinhardt<sup>1</sup>,  
B. von Tresckow<sup>1</sup>, F. Rambow<sup>2</sup>, C. Mlynarczyk<sup>5</sup>, E. Kocakavuk<sup>1,2</sup>  
<sup>1</sup> University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany  
<sup>2</sup> University Hospital Essen, Institute for AI in Medicine, Essen, North Rhine-Westphalia, Germany  
<sup>3</sup> University Hospital Essen, Department of Neuropathology, Essen, North Rhine-Westphalia, Germany  
<sup>4</sup> University Hospital Essen, Department of Pathology, Essen, North Rhine-Westphalia, Germany  
<sup>5</sup> Yale University, Yale School of Medicine, New Haven, Connecticut, United States of America
- PO\_C10**                    **Exploring NR4A1-associated transcriptional programs in lymphoma at single-cell resolution**  
**A. Zupo**<sup>1</sup>, S. Haingartner<sup>1</sup>, J. Feichtinger<sup>2</sup>, F. Vagena<sup>3</sup>, K. Pansy<sup>1</sup>, A. Deutsch<sup>1</sup>  
<sup>1</sup> Medical University of Graz, Department of Hematology, Graz, Steiermark, Austria  
<sup>2</sup> Medical University of Graz, Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Graz, Steiermark, Austria  
<sup>3</sup> Medical University of Graz, Institute of Pathology, Graz, Steiermark, Austria
- PO\_C11**                    **Loss of *ETV6* enhances lymphomagenesis in a murine model of diffuse large B cell lymphoma in a cell-of-origin dependent manner**  
**S. Höfmann**<sup>1</sup>, A. Tabatabai<sup>1</sup>, R. Flümann<sup>2,3</sup>, S. Klein<sup>1</sup>, I. Kisis<sup>1</sup>, R. Öllinger<sup>4</sup>,  
M. Möllmann<sup>1</sup>, M. Hartnack<sup>1</sup>, S. Kesper<sup>1</sup>, A. Arora<sup>1</sup>, B. von Tresckow<sup>1</sup>,  
R. D. Jachimowicz<sup>2,5</sup>, R. Rad<sup>4,6</sup>, G. Knittel<sup>1</sup>, H. C. Reinhardt<sup>1</sup>  
<sup>1</sup> University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany  
<sup>2</sup> Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, North Rhine-Westphalia, Germany  
<sup>3</sup> University Hospital of Cologne, Center for Molecular Medicine, Cologne, North Rhine-Westphalia, Germany  
<sup>4</sup> Technische Universität München, Institute of Molecular Oncology and Functional Genomics, School of Medicine, Munich, Bavaria, Germany  
<sup>5</sup> Max Planck Institute for Biology of Ageing, Cologne, North Rhine-Westphalia, Germany  
<sup>6</sup> Technische Universität München, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Munich, Bavaria, Germany

**PO\_D1 to PO\_D11**

Chair: Ralf Küppers, University Hospital Essen (GER)

**PO\_D1**

**Generation of Faithful Autochthonous Mouse Models of Mantle Cell Lymphoma**

**N. A. Mönig**<sup>1,2</sup>, C. M. Gräf<sup>1,2</sup>, P. J. Bröckelmann<sup>1,2</sup>, C. Bruzeau<sup>1</sup>, Y. Taskiran<sup>1</sup>, M. Reese<sup>1,2</sup>, A. Becker<sup>1,2</sup>, G. Knittel<sup>4</sup>, H. C. Reinhardt<sup>4</sup>, M. Thelen<sup>1,2</sup>, R. D. Jachimowicz<sup>1,2</sup>

<sup>1</sup> Max Planck Institute for Biology of Ageing, Mechanisms of DNA Repair, Cologne, North Rhine-Westphalia, Germany

<sup>2</sup> University Hospital of Cologne, Department I of Internal Medicine, Cologne, North Rhine-Westphalia, Germany

<sup>3</sup> University Duisburg-Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

**PO\_D2**

**Linear ubiquitin is critical for transformation and immune evasion of diffuse large B-Cell Lymphoma**

**D. Bonasera**<sup>1,2</sup>, J. Saggau<sup>1,2</sup>, A. Langpape<sup>1,2</sup>, J. Valiulis<sup>3</sup>, A. Florin<sup>4</sup>, M. Peifer<sup>3</sup>, J. Löber<sup>5</sup>, B. Chapuy<sup>5,6</sup>, R. Büttner<sup>4</sup>, H. C. Reinhardt<sup>7</sup>, E. Rieser<sup>2,1</sup>, A. Montinaro<sup>8</sup>, G. Liccardi<sup>1,2</sup>, H. Walczak<sup>1,2</sup>

<sup>1</sup> Uniklinik, University Hospital of Cologne, Institute of Biochemistry I, Cologne, North Rhine-Westphalia, Germany

<sup>2</sup> Uniklinik, University Hospital of Cologne, CECAD Cluster of Excellence, Cologne, North Rhine-Westphalia, Germany

<sup>3</sup> University Hospital of Cologne, Department of Translational Genomics, Cologne, North Rhine-Westphalia, Germany

<sup>4</sup> Uniklinik, University Hospital of Cologne, Institute of Pathology, Cologne, North Rhine-Westphalia, Germany

<sup>5</sup> Charité-Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Berlin, Germany

<sup>6</sup> Charité-Universitätsmedizin Berlin, German Cancer Consortium, Berlin, Berlin, Germany

<sup>7</sup> University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

<sup>8</sup> University College London, UCL Cancer Institute, London, United Kingdom

PO\_D3

**Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell/histiocyte-rich large B-Cell Lymphoma identified by whole genome sequencing**

T. Rausch<sup>3</sup>, H. Schäfer<sup>1</sup>, J. Bein<sup>5</sup>, F. Mölder<sup>6</sup>, L. Beeck<sup>6</sup>, B. Kölsch<sup>1</sup>, S. Borchert<sup>1</sup>, V. Benes<sup>3</sup>, T. Halbsguth<sup>2</sup>, U. Brunnberg<sup>2</sup>, T. Oellerich<sup>2</sup>, T. Tousseyn<sup>4</sup>, M. Ponzoni<sup>7</sup>, M.-L. Hansmann<sup>5</sup>, J. Köster<sup>6</sup>, R. Küppers<sup>6</sup>, **S. Hartmann<sup>1</sup>**

<sup>1</sup> University Hospital Essen, Institute for Pathology, Essen, North Rhine-Westphalia, Germany

<sup>2</sup> University Hospital Frankfurt, Internal Medicine 2, Frankfurt, Hesse, Germany

<sup>3</sup> EMBL, Heidelberg, Baden-Württemberg, Germany

<sup>4</sup> University Hospital KU Leuven, Pathology, Leuven, Belgium

<sup>5</sup> University Hospital Frankfurt, Frankfurt, Hesse, Germany

<sup>6</sup> University Hospital Essen, Essen, North Rhine-Westphalia, Germany

<sup>7</sup> Scientific Institute San Raffaele, Pathology, Milan, Italy

PO\_D4

**Targeting MCT1 to Overcome Immunometabolic Resistance in Diffuse Large B-Cell Lymphoma**

**A. Lütz<sup>1</sup>**, J. Petri<sup>1</sup>, L. Schiffer<sup>1</sup>, S. Lund<sup>2</sup>, T. Behringer<sup>2</sup>, S. Seghezzi<sup>3</sup>, C. Orschel<sup>1</sup>, A.-C. Neumann<sup>1,3</sup>, S. Borchmann<sup>1</sup>, R. Ullrich<sup>1</sup>, S. Scheich<sup>2</sup>, C. Frezza<sup>3</sup>, R. Flümman<sup>1</sup>

<sup>1</sup> Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

<sup>2</sup> University Hospital Frankfurt, Oncology Hematology, Frankfurt, Germany

<sup>3</sup> University Hospital of Cologne, Cluster of Excellence for Aging Research CECAD, Cologne, Germany

PO\_D5

**IRF2BP2: A novel tumor suppressor in diffuse large B-Cell Lymphoma**

**A. Tabatabai<sup>1</sup>**, M. Möllmann<sup>1</sup>, M. Hartnack<sup>1</sup>, G. Knittel<sup>1</sup>, C. Reinhardt<sup>1</sup>

<sup>1</sup> University Hospital Essen, Essen, Germany

PO\_D6

**Optimising Base Editing to Identify Novel Translated Microproteins in B Cell Lymphoma**

**E. G. Whittle<sup>1</sup>**, J. Krupka<sup>1</sup>, G. Scevchenko<sup>1</sup>, R. Jackson<sup>1</sup>, D. J. Hodson<sup>1</sup>

<sup>1</sup> University of Cambridge, Department of Haematology, Cambridge, United Kingdom

PO\_D7

**Comprehensive analysis of bridging to CAR T-cell therapy in large B-Cell Lymphoma with conventional treatment or CD3xCD20 bispecific antibodies**

M.A.-C. Neumann<sup>1,2</sup>, H. K. Zieger<sup>4</sup>, **R. Fluemann<sup>1,3</sup>**, N. Sieg<sup>1,5</sup>, A. Luetz<sup>1,5</sup>, J.K. Schleifenbaum<sup>1,2</sup>, S. Theobald<sup>5</sup>, M. Thelen<sup>6,7</sup>, C.-A. Voltin<sup>8</sup>, J. Ferdinandus<sup>1,2</sup>, M. Teichert<sup>4</sup>, K. Hörster<sup>4</sup>, V.C. Ridder<sup>4</sup>, E. Shumilov<sup>9</sup>, J. K. Scholz<sup>10</sup>, H. Huber<sup>11,12</sup>, R. I. Wurm-Kuczera<sup>13</sup>, F. Eigendorff<sup>14</sup>, F. Eisele<sup>15</sup>, G. Magno<sup>16,17</sup>, P. Schommers<sup>1</sup>, M. Szameitat<sup>1</sup>, J. Schneider<sup>1</sup>, S. Seghezzi<sup>18</sup>, D. Stahl<sup>1,2</sup>, P.J. Bröckelmann<sup>19,20</sup>, D. Bachurski<sup>1,2</sup>, N. Kutsch<sup>1,2</sup>, P. Gödel<sup>1,2</sup>, J. Meinel<sup>21</sup>, J. Rosenbrock<sup>22</sup>, I. Halmer<sup>1</sup>, M. Gräf<sup>1,2</sup>, M. Reese<sup>1,20</sup>, H. C. Reinhardt<sup>4</sup>, G. Lenz<sup>9</sup>, F. Müller<sup>10</sup>, B. Chapuy<sup>13</sup>, U. Schnetzke<sup>14</sup>, M. Topp<sup>15</sup>, V. Bücklein<sup>16</sup>, D.A. Eichenauer<sup>1</sup>, S. Borchmann<sup>1,19</sup>, J.-M. Heger<sup>1,2</sup>, P. Borchmann<sup>1,2</sup>, R.D. Jachimowicz<sup>1,20</sup>, **B. von Tresckow<sup>4</sup>**

- <sup>1</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany
- <sup>2</sup> Cologne Lymphoma Working Group (CLWG), Cologne, Germany
- <sup>3</sup> Faculty of Medicine and University Hospital Cologne, Institute for Metabolomics in Ageing, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany
- <sup>4</sup> Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- <sup>5</sup> Institute for Molecular Immunology, University Hospital of Cologne, Cologne, Germany
- <sup>6</sup> Department of General, Visceral, Thoracic, and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- <sup>7</sup> Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- <sup>8</sup> Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- <sup>9</sup> Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
- <sup>10</sup> Department of Medicine 5 - Haematology and Oncology University Hospital Erlangen, Erlangen, Germany
- <sup>11</sup> Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
- <sup>12</sup> Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany
- <sup>13</sup> Department of Hematology, Oncology and Cancer Immunology Charité Charité - Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany
- <sup>14</sup> Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
- <sup>15</sup> Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
- <sup>16</sup> LMU University Hospital, Department of Medicine III, Hematology/Oncology, Munich, Munich, Germany
- <sup>17</sup> German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- <sup>18</sup> University Hospital of Cologne, Faculty of Mathematics and Natural Sciences, Institute for Genetics, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany
- <sup>19</sup> German Hodgkin Study Group (GHSB), Cologne, Germany
- <sup>20</sup> Max Planck Institute for Biology of Ageing, Cologne, Germany
- <sup>21</sup> Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- <sup>22</sup> Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

**PO\_D8**

**Building a Genomic Meta-Cohort of 1,029 Primary CNS Lymphoma: Age-Associated Mutational Patterns from 27 Harmonized Cohorts**

**M. Tembrink**<sup>1,2</sup>, N. Freund<sup>1</sup>, C. Mlynarczyk<sup>4</sup>, S. Alig<sup>1</sup>, C. Reinhardt<sup>1</sup>, B. von Tresckow<sup>1</sup>, B. Pelzer<sup>3</sup>, E. Kocakavuk<sup>1,2</sup>

<sup>1</sup>University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

<sup>2</sup>University Hospital Essen, Institute for AI in Medicine (IKIM), Essen, North Rhine-Westphalia, Germany

<sup>3</sup>Cornell University, Weill Cornell Medicine, Ithaca, New York, United States of America

<sup>4</sup>Yale University, Yale School of Medicine, New Haven, Connecticut, United States of America

**PO\_D9**

**Genomic landscape of pediatric and adolescent Hodgkin lymphoma**

**M. Dörrbecker**<sup>1</sup>, T. Jox<sup>2</sup>, A. Rredhi<sup>2</sup>, P. Görtz<sup>2</sup>, R. Schmitz<sup>2</sup>, D. Körholz<sup>3</sup>, C. Mauz-Körholz<sup>3</sup>, S. Gattenlöhner<sup>2</sup>, M. Bartkuhn<sup>1</sup>, **A. Bräuninger**<sup>2</sup>

<sup>1</sup>Justus Liebig University Giessen, Biomedical Informatics and Systems Medicine Science Unit for Basic and Clinical Medicine, Giessen, Germany

<sup>2</sup>Justus Liebig University Giessen, Institute for Pathology, Giessen, Germany

<sup>3</sup>Justus Liebig University Giessen, Pediatric Hematology and Oncology Department, Giessen, Germany

**PO\_D10**

**Targeting Wnt/ $\beta$ -Catenin–PI3K/AKT Crosstalk: Insight into lineage restricted B-Cell Oncogenic Co-Operation**

**S. Kumar**<sup>1</sup>, P. Munch<sup>1</sup>, E. Zurkowski<sup>1</sup>, B. Clausen<sup>1</sup>, T. Wunderlich<sup>2</sup>, N. Hovelmeyer<sup>1</sup>

<sup>1</sup>Universitätsmedizin der Johannes Gutenberg-Universität, Institute for Molecular Medicine, Mainz, Rhineland-Palatinate, Germany

<sup>2</sup>Max Plank Institute for Metabolism Research, Obesity and Cancer, Cologne, North Rhine-Westphalia, Germany

**PO\_D11**

**BRD4 inhibition sensitizes diffuse large B-Cell Lymphoma cells to ferroptosis**

**A. Schmitt**<sup>1</sup>, H. Junge<sup>1</sup>, N. Kreienkamp<sup>1</sup>, P. Klener<sup>2</sup>, A. Dolnikova<sup>2</sup>, G. Lenz<sup>1</sup>, S. Hailfinger<sup>1</sup>

<sup>1</sup>University Hospital Münster, Department of Medicine A, Münster, North Rhine-Westphalia, Germany

<sup>2</sup>Charles University Prague, Institute of Pathological Physiology, Prague, Czech Republic

**Gemeinsam**  
Grenzen bei Krebs  
**verschieben**

# FORTSCHRITTE entstehen im Miteinander

Engagement, Innovationsgeist und Partnerschaften ermöglichen es uns, Menschen mit Krebs neue Lebensperspektiven zu eröffnen. Denn unsere konsequente Forschung führt zu Medikamenten, mit denen **stetig der Therapiestandard verbessert** werden kann.

Doch echte Fortschritte entstehen vor allem im **Miteinander** – mit Wissenschaft, Medizin und Patientenorganisationen.

**FÜR EINE ZUKUNFT VON MENSCHEN MIT KREBS.**

Day 3 | Saturday, May 23, 2026

- 9:00-11:05**      **SESSION 6**  
**Molecular characterization and dynamic disease monitoring in lymphoma**  
**Chairs**      Ari M. Melnick, Josep Carreras Leukaemia (ES)  
Sandrine Roulland, CIML-Centre d' Immunologie, Marseille-Luminy (FR)
- .....
- 9:00**      **Minimally Invasive Technologies for Profiling Lymphomas and Their Microenvironment**  
Ash A. Alizadeh, Stanford University / Stanford Comprehensive Cancer Center (USA)
- 9:25**      **Molecularly Defined Classic Hodgkin Lymphoma Subtypes**  
Stefan Alig, University Hospital Essen (GER)
- 9:50**      **Molecular characterization and liquid biomarker strategies in primary CNS lymphoma**  
Florian Scherer, University of Freiburg (GER)
- 10:15–10:25**      **Short talk I**  
***Bypassing Heterogeneity: Targeting a Lineage-Specific Dependency in Germinal Centre–Derived B-Cell Lymphoma***  
**R. A. Jackson**; E. G. Whittle; H. Runge; W. Zhou; Y. Wang, Cambridge (UK); S. Kolsuz, Istanbul (TR); D. Hodson, Cambridge (UK)
- 10:30–10:40**      **Short talk II**  
***Relapse-founding progenitor cells in follicular lymphoma***  
**O. Atkins**; M.S. Hung; O.-R. Song; B. Chen; B. Maybury; C. Edmondson, London (UK); B. Tesson, Pierre-Bénite (FR); S. Huet, Lyon (FR); G. Salles, New York (USA); M. Howell, London (UK); H. C. Reinhardt, Essen (GER); J. Fitzgibbon; J. Okosun; L. Zhang, London (UK); D. P. Calado, London and Cambridge (UK)
- 10:40**      **Developing multi-agent therapies targeting oncogenic pathways in aggressive lymphomas**  
Louis Staudt, National Cancer Institute Bethesda (USA)
- 11:05–11:35**      Break

11:35-2:30

**SESSION 7**

**Molecular decoding of lymphomagenesis**

**Chairs**

Christian Reinhardt, University Hospital Essen (GER)

Margaret Shipp, Dana Farber/Harvard Cancer Center, Boston (USA)

.....

11:35

**Mouse models of mantle cell lymphoma**

Ron Jachimowicz, University Hospital Cologne (GER)

12:00

**Mechanisms of germinal center B cell competition and CNS infiltration in DLBCL**

Coraline Mlynarczyk, Cancer Center Yale University

School of Medicine / New Haven (USA)

12:25

**Molecular characterisation and heterogeneity of follicular lymphoma transformation**

Jessica Okosun, Queen Mary University of London (UK)

12:50

**Genetics-driven Epigenetic Deregulation in B cell lymphomas**

Laura Pasqualucci, Columbia University New York (USA)

1:15

**Deciphering the Genomics of Aggressive Lymphoma**

Daniel Hodson, University of Cambridge (UK)

1:40

**The Roads Less Traveled: Extra-Follicular Pathways in DLBCL Development**

Benedikt Pelzer, University Hospital Essen (GER)

2:05

**Mouse models of genetically-driven DLBCL immune states and immunotherapy outcomes**

José Ángel Martínez Climent, University of Navarra (ES)

2:30

**Closing remarks**

Farewell and Goodbye

DEN FUNKEN  
NEU  
ENTFACHEN

Bei r/r MCL & r/r CLL  
post-cBTKi zugelassen<sup>1</sup>

Wenn ein kovalenter BTK-Inhibitor\*  
bei chronischer lymphatischer Leukämie (CLL) keine Option mehr ist<sup>+</sup>

Die Vorteile der BTK-Inhibition mit Jaypirca® nutzen<sup>1</sup>

Nachgewiesene  
Wirksamkeit<sup>1,2</sup>

Günstiges  
Verträglichkeitsprofil<sup>1,2</sup>

Einfaches  
Dosierschema<sup>1</sup>

**14.0**

Monate mPFS

(95 %-KI: 11.2, 16.6)

vs. 8.7 Monate

(95 %-KI: 8.1, 10.4)

für IdR/BR<sup>2</sup>

**24.0**

Monate mTTNT<sup>†</sup>

(95 %-KI: 17.8, 29.7)

vs. 10.9 Monate

(95 %-KI: 8.7, 12.5)

für IdR/BR<sup>2</sup>

**5%**

Abbruchrate

aufgrund von  
behandlungsbedingten UEs

vs. 21 % für IdR/BR<sup>2a</sup>

**1x**

täglich

Zwei Tabletten

Jaypirca®  
Pflichttext



<sup>†</sup> Sekundärer Endpunkt. Erlaubt keine statistischen Schlussfolgerungen.<sup>2</sup>

Jaypirca® als Monotherapie ist indiziert zur Behandlung von erwachsenen Patient:innen mit rezidivierendem oder refraktärem Mantelzell-Lymphom (MCL) und erwachsenen Patient:innen mit rezidivierender oder refraktärer chronischer lymphatischer Leukämie (CLL), die zuvor mit einem Bruton-Tyrosinkinase (BTK)-Inhibitor behandelt wurden.<sup>1</sup>

\* Ibrutinib, Acalabrutinib, Zanubrutinib.<sup>3</sup> <sup>+</sup> «Keine Option mehr ist» bezieht sich auf eine Krankheitsprogression.<sup>1</sup> <sup>a</sup> Zahlen sind gerundet.

**2L:** Zweitlinie; **BTK:** Bruton-Tyrosinkinase; **BTKi:** BTK-Inhibitor; **cBTKi:** kovalenter Bruton-Tyrosinkinase-Inhibitor; **IdR/BR:** Idelalisib plus Rituximab oder Bendamustin plus Rituximab; **KI:** Konfidenzintervall; **MCL:** Mantelzell-Lymphom; **mPFS:** medianes progressionsfreies Überleben; **mTTNT:** mediane Zeit bis zur nächsten Behandlung; **r/r:** rezidiviert oder refraktär; **UE:** Unerwünschte Ereignisse.

**Referenzen:** **1.** Jaypirca® Fachinformation (aktueller Stand). **2.** Sharman JP, et al. J Clin Oncol. 2025;00(00):1–12. **3.** Wen T, et al. Leukemia. 2021;35(2):312–332.

**4.** Chronische Lymphatische Leukämie (CLL) - Onkopedia.

<https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html>. Letzter Zugriff: Januar 2026.

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden.

 **A MEDICINE COMPANY**



## Faculty | Speakers, in alphabetical order<sup>1</sup>



**STEFAN ALIG**

Department of Hematology and Stem Cell Transplantation  
West German Cancer Center  
University Hospital Essen  
Essen, GER

.....



**ASH A. ALIZADEH**

Professor of Medicine  
Stanford University | Stanford Comprehensive Cancer Center  
Stanford, USA

.....



**DARKO BARISIC**

Division of Hematology & Medical Oncology  
Weill Cornell Medicine  
New York, USA

.....



**WENDY BÉGUELIN**

New York City University  
Langone Health  
New York, USA

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**PETER BORCHMANN**

Clinic for Internal Medicine Oncology/ Haematology  
University Hospital Cologne  
Cologne, GER

.....



**PAUL BRÖCKELMANN**

Department I of Internal Medicine and German Hodgkin Study Group  
University Hospital of Cologne  
Cologne, GER

.....



**BJÖRN CHAPUY**

Charité University Medicine Berlin  
Berlin, GER

.....



**SASCHA DIETRICH**

Director of the Clinic for Haematology, Oncology and Clinical Immunology  
University Hospital Düsseldorf  
Düsseldorf, GER

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**MICHAEL GREEN**

Professor and Vice Chair for Research  
Department of Lymphoma & Myeloma  
University of Texas MD Anderson Cancer Center  
Houston, USA

.....



**DANIEL HODSON**

Cambridge Stem Cell Institute  
University of Cambridge  
Cambridge, UK

.....



**MICHAEL HUDECEK**

Medical Clinic and Polyclinic II  
Chair of CI /NCT WERA  
University Hospital Würzburg  
Würzburg, GER

.....



**MARTIN HUTCHINGS**

Senior consultant, Department of Haematology and Phase 1 Unit  
Rigshospitalet, Copenhagen  
Professor, Department of Clinical Medicine  
University of Copenhagen  
Copenhagen, DK

<sup>1</sup>All information as provided by the respective speaker.

Faculty | Speakers, in alphabetical order<sup>1</sup>



**RON JACHIMOWICZ**

Clinic for Internal Medicine Oncology/Hematology  
Max-Planck-Institute for Biology of Ageing  
University Hospital Cologne  
Cologne, GER

.....



**GEMMA KELLY**

Professor  
Walter and Eliza Hall Institute of Medical Research  
Melbourne, AUS

.....



**STEFAN KNAPP**

Professor of Pharmaceutical Chemistry  
CSO Structural Genomics Consortium, Frankfurt  
Institute of Pharmaceutical Chemistry  
Goethe-University Frankfurt  
Frankfurt, GER

.....



**SEBASTIAN KOBOLD**

Division of Clinical Pharmacology  
LMU Klinikum München  
Munich, GER

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**RALF KÜPPERS**

Deputy Managing Director  
Institute for Cell Biology (cancer research)  
University Hospital Essen  
Essen, GER

.....



**GEORG LENZ**

Director  
University Hospital Münster  
Münster, GER

.....



**JOSÉ ÁNGEL MARTÍNEZ CLIMENT**

University of Navarra  
Navarra, ES

.....



**ARI M. MELNICK**

Director  
Josep Carreras Leukaemia  
Research Institute  
Barcelona, ES

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**CORALINE MLYNARCZYK**

Assistant Professor of Medicine  
Yale Cancer Center & Center of Molecular & Cellular Oncology  
Yale University School of Medicine  
New Haven, USA

.....



**THOMAS OELLERICH**

Director  
Department of Hematology, Oncology, Hemostaseology,  
Rheumatology and Infectious Diseases  
University Medical Center Frankfurt  
Frankfurt, GER

.....



**JESSICA OKOSUN**

Professor of Translational Cancer Research  
Barts Cancer Institute  
Queen Mary University of London  
London, UK

.....



**ERIN M. PARRY**

Assistant Professor of Medicine, Harvard Medical School  
Physician, Dana-Farber Cancer Institute  
Boston, USA

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**LAURA PASQUALUCCI**

Professor of Pathology and Cell Biology  
Institute for Cancer Genetics  
Columbia University  
New York, USA

.....



**BENEDIKT PELZER**

West German Cancer Center  
University Hospital Essen  
Essen, GER

.....



**JAMES D. PHELAN**

Center for Cancer Research  
National Cancer Institute  
Bethesda, USA

.....



**CHRISTIAN REINHARDT**

Director, Department of Haematology and Stem Cell Transplantation  
West German Cancer Center  
University Hospital Essen  
Essen, GER

<sup>1</sup>All information as provided by the respective speaker.

Faculty | Speakers, in alphabetical order<sup>1</sup>



**MARK ROSCHEWSKI**

Memorial Sloan Kettering Cancer Center  
New York, USA

.....



**SANDRINE ROULLAND**

Centre d'Immunologie Marseille-Luminy  
Parc Scientifique et Technologique de Luminy  
Marseille, FR

.....



**ROMAN C. SARROT**

Max-Planck-Institute for Medical Research  
Heidelberg, GER

.....



**SEBASTIAN SCHEICH**

Department of Hematology and Oncology  
University Hospital Frankfurt  
Frankfurt, GER

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**FLORIAN SCHERER**

Department of Hematology and Oncology  
University Medical Center Freiburg  
Freiburg, GER

.....



**MARGARET SHIPP**

Douglas Miller Chair in Lymphoma  
Dana-Farber Cancer Institute  
Professor, Harvard Medical School  
Boston, USA

.....



**REINER SIEBERT**

Professor of Human Genetics  
Director, Institute of Human Genetics  
Vice-Director, Center of Rare Diseases  
Ulm University Medical Center  
Ulm, GER

.....



**LOUIS M. STAUDT**

Director, Center for Cancer Genomics  
Chief, Lymphoid Malignancies Branch  
National Cancer Institute  
Bethesda, USA

## Faculty | Speakers, in alphabetical order<sup>1</sup>



**CHRISTIAN STEIDL**

Professor, Department of Pathology and Laboratory Medicine  
University of British Columbia  
Vancouver, CAN

.....



**ROLAND ULLRICH**

Clinic for Internal Medicine  
University Hospital Cologne  
Cologne, GER

.....



**BASTIAN VON TRESCKOW**

Deputy Director, Department of Haematology and Stem Cell Transplantation  
West German Cancer Center  
University Hospital Essen  
Essen, GER

.....



**JASON WESTIN**

Professor, Department of Lymphoma & Myeloma  
Director, Lymphoma Clinical Research  
Section Chief, Aggressive and Indolent Lymphoma  
University of Texas MD Anderson Cancer Center  
Houston, USA

## Sponsors and Exhibitors

### MAIN SPONSORS

---

abbvie

Johnson & Johnson

Lilly



### THANK YOU ALL VERY MUCH

---

 Bristol Myers Squibb™

 sobi

 BeOne

 GILEAD  
Creating Possible

 Takeda

In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services. Net amounts, before deduction of costs. Total cost of the conference: approx. € 250,000. AbbVie Deutschland GmbH & Co. KG - € 50,000, BeOne Medicines Germany GmbH - € 5,000, Bristol-Myers Squibb GmbH & Co. KGaA - € 10,000, GILEAD Science GmbH - € 5,000, Janssen-Cilag GmbH/Johnson & Johnson - € 50,000, Lilly Deutschland GmbH - € 50,000, Roche Pharma AG - € 50,000, sobi Swedish Orphan Biovitrum GmbH - € 10,000, Takeda Pharma Vertrieb GmbH & Co. KG - € 5,000. Status: 05/2026



Medizinische Durchbrüche erzielen & Leben von Menschen verbessern

Unser Ziel ist ambitioniert: die Welt ohne Krebs. Unsere Forscher:innen suchen jeden Tag nach medizinischen Lösungen, die das möglich machen können.

Dabei sind die individuellen Bedürfnisse von Menschen mit Krebs unsere größte Motivation: Ihr Leben wollen wir entscheidend verbessern.

So verbinden wir das Beste aus Health&Care:  
Medizinische Innovation mit dem Menschen im Mittelpunkt.

[jnj.com/innovativemedicine/germany](https://www.jnj.com/innovativemedicine/germany)

**Johnson & Johnson**  
**The Health & Care Company**

[www.lymphoma-symposium.de](http://www.lymphoma-symposium.de)

All information and data correspond to the status at the time of printing. Subject to change.  
Despite careful editing, all information is subject to change without guarantee. Status 05/2026.